One of the challenges with initiating long-acting injectable (LAI) antipsychotic regimens is achieving relevant drug levels quickly. After first injection of the LAI antipsychotic aripiprazole lauroxil (AL), the lag to reaching relevant plasma aripiprazole levels was initially addressed using supplemental oral aripiprazole for 21 days. A 1-day AL initiation regimen using a NanoCrystal® Dispersion formulation of AL (ALNCD; Aristada Initio®) combined with a single 30 mg dose of oral aripiprazole has been developed as an alternative approach. We compared the 1-day AL initiation regimen (ALNCD + 30 mg oral aripiprazole for 1 day) with the 21-day AL initiation regimen (AL + 15 mg/day of oral aripiprazole for 21 days) using kinetic modeling. Observed and modeled data demonstrate that the 1-day AL initiation regimen provides continuous aripiprazole exposure comparable to the 21-day AL initiation regimen. Each component of the 1-day AL initiation regimen (30 mg oral aripiprazole, ALNCD, and AL) contributes to aripiprazole plasma levels at different times, with oral aripiprazole predominating in the first week, then ALNCD and AL over time. In a double-blind, placebo-controlled, phase 1 study in patients with schizophrenia, the 1-day initiation regimen resulted in rapid achievement of relevant plasma aripiprazole levels comparable to those from the 21-day initiation regimen. Safety and tolerability of the 1-day regimen were consistent with the known profile of aripiprazole. Each part of the 1-day initiation regimen, together with AL, is necessary for continuous aripiprazole exposure from treatment initiation until the next regularly scheduled AL injection is administered.

Received 30 January 2019; Accepted 11 February 2019; First published online 21 May 2019

Key words: Long-acting injectable antipsychotic, oral supplementation, kinetics, plasma levels, medication adherence, aripiprazole lauroxil.

Introduction

Slow release is a fundamental feature of long-acting injectable (LAI) antipsychotics that allows continuous drug exposure between injections. Drugs formulated for a slow rate of dissolution are released into plasma over an extended period and produce sustained plasma drug levels permitting dosing intervals from weeks to months.

However, the slow dissolution can also result in a significant delay in achieving plasma drug levels associated with symptom improvement when initiating some LAI antipsychotics. This delay has been addressed using one of two strategies: (1) “loading dose” approaches using initial injections delivered more frequently (e.g., weekly) than the dosing interval used for the maintenance dose or (2) prescribing an oral antipsychotic for bridging during the LAI initiation period.

Aripiprazole lauroxil (AL; Aristada®), a prodrug of aripiprazole, is an LAI antipsychotic approved for the treatment of schizophrenia in adults. The AL formulation is an injectable suspension of micrometer-sized particles designed for slow dissolution (Figure 1). The rate of dissolution, or release of the drug from the particles, allows for a dosing interval of up to 2 months. But the same
slow-release attribute of AL also means that it takes between 6 and 7 weeks for aripiprazole to reach peak plasma levels. For other LAIs, this lag time has traditionally been addressed in one of two ways. A loading dose approach has been used for other LAI antipsychotic formulations (e.g., haloperidol decanoate, fluphenazine decanoate, and paliperidone palmitate); however, this approach would not work for AL because this lag time is independent of initial dosing strength and, therefore, would not appreciably change the time delay that occurs before the achievement of relevant aripiprazole levels. Instead, a second option is used to address the lag time between the first AL injection and achievement of relevant plasma drug levels, which involves oral aripiprazole supplementation for the first 21 days with AL initiation.

Adherence to a 21-day oral-dose regimen may be difficult for some patients starting an LAI medication. Nonadherence rates are notably high for oral antipsychotics, with reported rates of partial or complete lack of adherence to antipsychotic medications as high as 25% within the first 10–14 days after hospital discharge. Indeed, it is often the patients who fail to adhere to oral antipsychotic medication who are candidates for LAI treatment. Obviously, these individuals may continue to struggle with adherence to even a short, 21-day oral aripiprazole supplementation regimen after their first AL injection. Consequently, these patients may benefit from an AL initiation regimen that provides relevant plasma aripiprazole levels early in the course of therapy, without the need for extended oral supplementation.

This paper describes a new strategy for starting AL therapy as an alternative to the 21-day oral aripiprazole supplementation that was the only option available when AL was initially approved for use by the US Food and Drug Administration. The clinical goal for embarking on this strategy was to reduce the time needed for oral supplementation to a single-day initiation of AL while providing plasma levels of aripiprazole that were comparable to those observed with the 21-day oral aripiprazole initiation regimen. To that end, a more rapidly dissolving formulation of AL, known as Aripiprazole Lauroxil NanoCrystal® Dispersion (ALncD), was developed that requires only a 1-day oral aripiprazole initiation regimen.

Particle size and drug kinetics

A key to the development of an AL formulation that has the specific characteristics needed to bridge the plasma aripiprazole level gap at AL initiation is the relationship between particle size and rate of dissolution. In general, larger particle size is associated with a slower rate of dissolution, as the rate of dissolution is related to the surface area-to-volume ratio for a given particle size. A nanometer-sized particle is 1000 times smaller than a micron-sized particle. Because of this, the surface area-to-volume ratio is up to 1000 times larger for a nanometer-sized particle than for its micrometer counterpart.

This net result is that a drug formulated with a smaller particle size has a different plasma concentration profile over time, or kinetics, than one with larger particle size. The observed kinetic profile that results with ALncD is characterized by a faster rise in plasma drug levels after administration, earlier peak plasma levels, and a shorter half-life than a formulation with a larger particle size (Figure 2). Manipulation of particle size to achieve specific kinetic profiles is a well-known strategy and was employed to develop the 3-month formulation of paliperidone palmitate (PP3M) (Invega Trinza®), Janssen Pharmaceuticals, Inc., Titusville, NJ, USA). In that example, a larger particle size was created from the 1-month formulation (PP1M) (Invega Sustenna®), Janssen Pharmaceuticals, Inc., Titusville, NJ, USA) to facilitate slower release with PP3M. Peak plasma drug levels are observed at 30–33 days post-injection for PP3M compared with approximately 7–8 days post-injection for the smaller particle PP1M formulation. The aim in developing a new AL initiation regimen, therefore, was to design an AL formulation with a smaller particle size that provided faster kinetics suitable for bridging the AL plasma aripiprazole gap with only a single 30 mg dose of oral aripiprazole, while replicating the kinetics of the original 21-day oral initiation regimen.

Development of a 1-day initiation regimen

The newly developed formulation is a NanoCrystal Dispersion of AL (Aristada Initio®), which contains the same prodrug that is in AL, but with nanometer-sized

![Visual Schema of an Aqueous-Based LAI Suspension](image-url)
particles instead of micrometer-sized particles. A comparison of the original AL formulation with the new ALNCD formulation is presented in Table 1. The smaller particle size of ALNCD results in faster dissolution of the drug than with AL, and administration of ALNCD was therefore expected to be associated with an earlier rise in plasma aripiprazole levels than with AL. The kinetics of ALNCD were investigated to determine whether this new formulation could provide an earlier rise in plasma aripiprazole levels (than AL) with adequate levels sustained over time such that it could be used in place of the 21-day oral-dose bridging regimen otherwise required for initiating AL therapy.

Plasma levels may vary from patient to patient administered the same dose of a single drug formulation, but population model-based simulations can be used to simulate average plasma levels over time for a population by aggregating numerous plasma concentrations collected after drug administration in multiple studies of drug kinetics. To characterize the kinetics of aripiprazole in plasma after ALNCD administration and to determine whether the new AL formulation could offer an alternative to the oral bridging regimen, observed data and population model-based simulations were used to predict plasma drug levels after administration of ALNCD, AL, or oral aripiprazole (Alkermes, Inc., data on file. Waltham, MA, USA; 2017).

Model-based simulations of plasma levels over time are compared for ALNCD and AL in Figure 3(a). As expected based on particle size, plasma aripiprazole levels rise more rapidly after a single injection of ALNCD vs. AL. After initial AL injection, predicted plasma aripiprazole levels rise slowly to peak at approximately 7-8 weeks, which is consistent with observed kinetics study results. In contrast, plasma aripiprazole levels are predicted to rise rapidly during the first week after an

---

**TABLE 1. Comparison of Aristada® and Aristada Initio®**

|                                | Aristada® (AL)                                  | Aristada Initio® (ALNCD)                          |
|--------------------------------|------------------------------------------------|--------------------------------------------------|
| **Rationale**                  | Ongoing treatment of schizophrenia              | Single use only as part of a 1-day initiation regimen when giving first dose of AL |
| **Drug product injected**      | Aripiprazole lauroxil                            | Aripiprazole lauroxil                             |
| **LinkeRx® technology**        | Yes                                             | Yes                                              |
| **NanoCrystal® technology**    | No                                              | Yes                                              |
| **Particle size in suspension**| Micrometer-sized particles                       | Nanometer-sized particles                         |
| **Dose strengths**             | Four strengths: 441, 662, 882, and 1064 mg      | One dose strength (675 mg)                        |
| **Injection volume**           | 1.6 mL (441 mg)                                 | 2.0 mL (675 mg)                                  |
|                                | 2.4 mL (662 mg)                                 |                                                  |
|                                | 3.2 mL (882 mg)                                 |                                                  |
|                                | 3.9 mL (1064 mg)                                |                                                  |
| **Site of injection**          | 441 mg dose is either deltoid or gluteal. Other dosage strengths are gluteal only | Either deltoid or gluteal                           |
| **Dose intervals**             | Monthly, every 6 weeks, every 2 months depending on the regimen chosen | Single dose when starting or restarting AL (not intended for repeated use) |

**FIGURE 2.** Kinetics of smaller vs. larger particle size formulations. $T_{\text{last}}$, time last measurable plasma drug concentration; $T_{\text{max}}$, time of peak plasma concentration.
A_NCD injection and peak at approximately 3–4 weeks (approximately 27 days after the A_NCD injection based on observed follow-up aripiprazole levels\textsuperscript{1}). However, although aripiprazole appears more rapidly in plasma after administration of A_NCD than AL, the rise is still slower with A_NCD than with oral aripiprazole.\textsuperscript{10} A comparison of plasma aripiprazole levels associated with A_NCD vs. a single 30 mg dose of oral aripiprazole shows that, after administration of A_NCD, a small but clinically significant gap in coverage remains (Figure 3(b)). These results indicate that a single A_NCD injection thus could cover most, but not all, of the gap in plasma aripiprazole levels at AL initiation than the 21-day oral aripiprazole supplementation regimen bridges.

The solution to this problem of the first week “shortfall” of aripiprazole levels after A_NCD injection came from pharmacokinetic modeling. It turned out that adding a single 30 mg dose of oral aripiprazole on day 1 was what was needed. Thus, giving a single injection of A_NCD along with a single 30 mg dose of oral aripiprazole on the same day would provide an equivalent duration of relevant aripiprazole levels as giving 21 days of oral aripiprazole at 15 mg/day. This concept, illustrated in Figure 3(b), suggests that adding a single 30 mg oral dose of aripiprazole at the time of the A_NCD injection will fill the aripiprazole plasma concentration gap associated with the initiation of AL treatment. Population model-based simulations showed that, when one 30 mg dose of oral aripiprazole was given at the same time as the A_NCD dose, plasma levels rose earlier and relevant levels were attained approximately a week earlier than in simulations without the oral aripiprazole dose (Alkermes, Inc., data on file. Waltham, MA, USA; 2017). These results demonstrate that the A_NCD injection and a single 30 mg dose of oral aripiprazole together provide the profile of plasma aripiprazole levels over time needed for an effective 1-day initiation of AL treatment.

Observed and simulated plasma aripiprazole levels were used to examine how the individual components (i.e., the single injection of A_NCD + a single 30 mg oral
dose of aripiprazole, together with the starting dose of AL, contribute to plasma aripiprazole levels through the first 8 weeks of AL therapy (Alkermes, Inc., data on file. Waltham, MA, USA; 2017). As shown in Figure 3(c), the kinetic profile of the combined administration of the two-component initiation regimen (i.e., \( AL_{NCD} + \) a single 30 mg dose of oral aripiprazole) with the first dose of AL reflects the additive, time-dependent result of all underlying components. The single dose of oral aripiprazole primarily contributes to plasma aripiprazole levels at the earliest time points, beginning on the day of injection. This is followed by the contribution from the \( AL_{NCD} \) injection, which peaks at approximately 27 days. Aripiprazole exposure from the AL starting dose then predominates after the initiation period. The timing of aripiprazole release from the three sources results in sustained plasma exposure, rising rapidly in the first few days and lasting until the next scheduled AL injection. Continuous coverage is provided with no need for further oral antipsychotic supplementation and without producing excessive plasma aripiprazole levels.

The direct test of the 1-day AL initiation regimen vs. 21 days of oral supplementation: exposure, safety, and tolerability

To determine whether the 1-day initiation regimen is comparable to the 21-day regimen, a phase 1, double-blind, placebo-controlled study in adult patients with schizophrenia initiating AL therapy was carried out to assess the kinetics, safety, and tolerability of the two regimens. The four-arm study compared the 1- and 21-day AL initiation regimens for two individual AL doses (441 or 882 mg administered monthly) as illustrated in Supplemental Figure 1. Patients assigned to the 1-day initiation regimen received a single \( AL_{NCD} \) injection given intramuscularly and a single 30 mg dose of oral aripiprazole administered together on day 1 and then received an oral placebo on days 2–21. Patients assigned to the 21-day initiation regimen were administered oral aripiprazole (15 mg/day) on days 1–21, with a placebo injection on day 1. Both 1- and 21-day initiation regimen groups were administered a single injection of AL (441 or 882 mg) on day 1.

Plasma aripiprazole levels were measured through the 21-day AL initiation period and then for 4 months afterward, and safety was monitored throughout the study with collection of adverse events (AEs). A total of 161 patients participated in the study. Their baseline demographic and clinical characteristics are shown in Supplemental Table 1.

Figure 4 shows study patients’ mean plasma aripiprazole levels for 28 days after administration of the 1-day vs. 21-day AL initiation regimens and first AL dose (Figure 4(a), AL 441 mg groups; Figure 4(b), AL 882 mg groups). The comparison between initiation regimens demonstrates that the 1-day initiation regimen of \( AL_{NCD} + \) a single 30 mg dose of oral aripiprazole results in rapid achievement of plasma aripiprazole levels comparable to the 21-day 15 mg/day oral aripiprazole initiation regimen and that aripiprazole levels persist through the first month after treatment initiation. Total aripiprazole exposure (the area under the curve) was also similar for the 1- and 21-day initiation regimen groups.

The safety profile of the 1-day initiation regimen was comparable to that of the 21-day initiation regimen and consistent with the known safety profile of aripiprazole and AL. AE rates were similar between patients in the 1- and 21-day initiation regimens (Supplemental Table 3). The incidence of akathisia, an AE associated with oral aripiprazole treatment, was relatively low (5% for the 1-day initiation regimen and 2.5% for the 21-day initiation regimen). There was no difference in severity of akathisia between the 1- and 21-day regimens. Injection site reactions – most commonly injection site pain – were reported by 17.5% of patients who received \( AL_{NCD} \) and 6.2% of patients who received placebo injections.

Using the 1-day initiation regimen in clinical practice

A new 1-day initiation regimen for AL has been developed using \( AL_{NCD} \) and a single oral 30 mg aripiprazole tablet. Each component of the 1-day regimen is needed, and these can both be given on the same day as the first dose of AL. There now are two ways to start AL therapy: either with 21 days of oral aripiprazole supplementation (15 mg/day), or, using the 1-day initiation regimen of a single injection of \( AL_{NCD} \) and a single 30 mg dose of oral aripiprazole instead. Data demonstrate that the 1-day initiation regimen may be used with any of the approved AL dosing regimens (441, 662, 882 mg q4 weeks; 882 mg q6 weeks; and 1064 mg q8 weeks) and provide relevant aripiprazole levels rapidly that are sustained for up to 2 months. The components of the 1-day regimen have complimentary kinetic profiles that together produce plasma aripiprazole levels that rise rapidly and remain sufficiently elevated until plasma aripiprazole levels from the second AL dose are sufficient (Alkermes, Inc., data on file. Waltham, MA; USA; 2017). The oral aripiprazole supplementation within the 1-day regimen is associated...
with the early rise in plasma aripiprazole that allows rapid achievement of relevant levels. The relatively rapid delivery of aripiprazole from the nanometer-sized AL\textsubscript{NCD} particles (vs. micrometer-sized AL particles) allows appropriate aripiprazole levels to be maintained until aripiprazole contributed by AL itself reaches target plasma levels. The double-blind, placebo-controlled, phase 1 study demonstrated that the kinetics of the two components of the new regimen replicate those of the 21-day oral regimen.

Based on these data, AL\textsubscript{NCD}, in combination with oral aripiprazole, has been approved by the US Food and Drug Administration and is available as a single-dose strength of 675 mg.\textsuperscript{21} The approved regimen, an AL\textsubscript{NCD} intramuscular injection administered together with a single 30 mg oral dose of aripiprazole, offers a 1-day AL initiation alternative to the original initiation strategy that required oral aripiprazole supplementation lasting 21 days.\textsuperscript{21} Although the 1-day initiation regimen was designed to be administered together with the first AL dose, AL\textsubscript{NCD} maintains target plasma aripiprazole levels long enough to allow the first AL dose to be administered up to 10 days after the 1-day AL\textsubscript{NCD} + 30 mg oral aripiprazole initiation regimen.\textsuperscript{15,21} AL\textsubscript{NCD} is approved for use only as a single dose in the AL initiation regimen and not for repeated dosing.\textsuperscript{21}
TABLE 2. Comparison of the 21- and 1-day initiation regimens for aripiprazole lauroxil

| Specifics of regimen | The 21-day oral initiation regimen | The 1-day initiation regimen |
|----------------------|-----------------------------------|------------------------------|
|                      | Prescribing oral aripiprazole for 21 days, along with first AL injection | Giving a single ALNCD IM injection and a single 30 mg oral aripiprazole dose along with the first AL injection |
| Flexibility of initiation dose | Daily oral aripiprazole dose given according to clinician judgment or total daily dose taken before AL initiation in accordance with prescribing information | Only one dose option for ALNCD and only 30 mg oral dose in accordance with prescribing information |
| Timing of initiation regimen with first AL injection | The 21 days of oral aripiprazole should be started on the day of the first AL injection | The ALNCD injection and single 30 mg oral aripiprazole dose can be given in any order as long as it is the same day. |
|                      | Recommend oral aripiprazole dose adjustments due to known drug-drug interactions | ALNCD dose is only available in one dose; cannot be modified and cannot be dose adjusted due to drug-drug interactions |
| Dose adjustments of initiation regimen | May be preferable when patient is motivated to complete the full 3 weeks of oral aripiprazole | Eliminates potential for nonadherence to oral aripiprazole; may be preferable when patient is likely to be nonadherent |
| Clinical considerations | May be preferable for clinicians who are already experienced and satisfied with 3-week initiation regimen | From day 1 of initiation, clinician is assured that appropriate aripiprazole levels are in the patient’s system until the next AL injection |
|                      | Preferable, with dose adjustment, in patients who are CYP2D6 poor metabolizers and in patients taking CYP3A4 inhibitors, CYP2D6 inhibitors, or CYP3A4 inducers for more than 2 weeks | Avoid use in patients who are known CYP2D6 poor metabolizers or taking strong CYP3A4 inhibitors, strong CYP2D6 inhibitors, or strong CYP3A4 inducers |
|                      | Consider initiation regimen if patient prefers one less injection | Avoid use in patients taking antihypertensive and/or benzodiazepines |
| Goal of initiation regimen | Both initiation regimens are used to provide appropriate aripiprazole levels for 3 weeks after the first AL injection | |
| Choice of first AL regimen | Both of these initiation regimens are suitable for any of the five AL dose/dose interval regimens | |
| Aripiprazole plasma levels | The two initiation regimens have comparable plasma aripiprazole levels and both achieve relevant plasma levels rapidly after initiation | |
| Need for prior aripiprazole exposure | In accordance with prescribing information, patients naive to aripiprazole must establish tolerability to aripiprazole before starting AL. Do not use either initiation regimen as a method for prior exposure | |
| Safety and tolerability | The safety profile of the 1-day initiation regimen is generally comparable to that of the 21-day initiation regimen and consistent with the known safety profile of AL | |

AL, aripiprazole lauroxil; ALNCD, Aripiprazole Lauroxil NanoCrystal® Dispersion; IM, intramuscular.

Prior to the approval of ALNCD, the only option for initiation of AL therapy was to prescribe 21 days of concomitant oral aripiprazole to provide relevant plasma levels during the slow dissolution of the AL dose.7 The availability of two options for initiating AL therapy, each offering different advantages, allows the clinician to choose the regimen best suited to the individual patient (Table 2). The 21-day oral supplementation regimen for AL initiation requires one fewer injection than does the 1-day AL initiation regimen; the 1-day initiation regimen, however, can be administered by the clinician in a single office visit. In addition, the 21-day AL initiation regimen should be used in patients who are cytochrome P450 (CYP) 2D6 poor metabolizers, in patients taking strong CYP 2D6 and/or CYP 3A4 inhibitors, and in patients taking strong CYP 3A4 inducers, whereas the 1-day AL initiation regimen using ALNCD should be avoided because no dose adjustment is possible for ALNCD. By eliminating the need for extended oral supplementation, the use of ALNCD + a single 30 mg dose of oral aripiprazole reduces pill burden and removes a potential barrier to adherence during initiation of AL therapy.22 Regardless of the regimens used, the two initiation options are comparable in terms of the plasma aripiprazole levels provided to bridge the gap at AL initiation, and the safety and tolerability of the two regimens are similar and consistent with the known profile of aripiprazole.19

Conclusion

ALNCD was developed to provide a rapid increase in plasma aripiprazole levels for a new, 1-day AL initiation strategy that is used in conjunction with the first dose of
AL. An ALNCGD injection administered together with a single 30 mg dose of oral aripiprazole composes a 1-day regimen that results in rapid achievement of aripiprazole levels comparable to the 21-day oral aripiprazole initiation regimen. Treatment with ALNCGD, in combination with a single 30 mg dose of oral aripiprazole dose and the starting dose of AL, was well tolerated in adult patients with schizophrenia. An initiation regimen for AL that uses one injection of ALNCGD plus a single 30 mg dose of oral aripiprazole offers a 1-day alternative to the 21-day oral aripiprazole bridging strategy for initiating treatment with AL.

Disclosures

Rakesh Jain has served as a consultant to Addrenex, Allergan, Avanir, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, and Teva; paid speaker for Addrenex, Alkermes, Allergan, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Rhodes, Shionogi, Shire, Sunovion, Takeda, and Tris Pharmaceuticals; received research support from Allergan, AstraZeneca, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda; and served on advisory board for Addrenex, Alkermes, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, and Teva. Jonathan Meyer reports having received speaking or advising fees from Acadia Pharmaceuticals, Alkermes, Allergan, Merck, Neurocrine, Otsuka America, Inc., Sunovion Pharmaceuticals and Teva Pharmaceutical Industries. Angela Wehr, Bhaskar Rege, Lisa von Molike, and Peter Weiden are employees of Alkermes, Inc.

Supplementary material

To view supplementary material for this article, please visit [https://doi.org/10.1017/S1092852919000816](https://doi.org/10.1017/S1092852919000816).

REFERENCES:

1. Ceskova E, Silhan P. Novel treatment options in depression and psychosis. *Neuropsychiatr Dis Treat*. 2018; 14: 741–747.
2. Invega Trinza [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2018.
3. Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. *Ther Adv Psychopharmacol*. 2014; 4(5): 196–219.
4. Melzner HY, Rösinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. *J Clin Psychiatry*. 2015; 76(8): 1085–1090.
5. Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. *Rev Recent Clin Trials*. 2012; 7(1): 2–9.
6. Aristada® [package insert]. Waltham, MA: USA: Alkermes, Inc.; 2018.
7. Ehret MJ, Davis E, Luttrell SE, et al. Aripiprazole lauroxil NanoCrystal® dispersion technology (Aristada Initio®). *Clin Schizophr Relat Psychoses*. 2018; 12(2): 92–96.
8. Hard ML, Mills RJ, Sadler BM, et al. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a Phase I study and a population pharmacokinetic model. *CNS Drugs*. 2017; 31(7): 617–624.
9. Turncliff R, Hard M, Du Y, et al. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. *Schizophr Res*. 2014; 159(2–3): 404–410.
10. Meyer JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. *CNS Spectrums*. 2017; 22(S1): 14–28.
11. Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. *J Clin Psychopharmacol*. 2016; 36(4): 355–371.
12. Velligan DI, Lam F, Ereshefsky L, et al. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. *Psychiatr Serv*. 2003; 54(5): 665–667.
13. Kane JM. Treatment strategies to prevent relapse and encourage remission. *J Clin Psychiatry*. 2007; 68(Suppl. 14): 27–30.
14. Leng D, Chen H, Li G, et al. Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size. *Int J Pharm*. 2014; 472(1–2): 380–385.
15. Hard ML, Wehr AY, Sadler BM, et al. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. *Eur J Drug Metab Pharmacokinet*. 2018; 43(4): 461–469.
16. Daghistani N, Rey JA. Invega Trinza: the first four-times-a-year, long-acting injectable antipsychotic agent. *J P T*. 2016; 41(4): 223–227.
17. Coppola D, Liu Y, Copal S, et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. *BMC Psychiatry*. 2012; 12: 26.
18. Abilify® [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd.; 2016.
19. Hard ML, Wehr AY, Du Y, et al. Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. *J Clin Psychopharmacol*. 2018; 38(5): 435–441.
20. Thomas JE, Caballero J, Harrington CA. The Incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. *Curr Neuropharmacol*. 2015; 13(5): 681–691.
21. Aristada Initio® [package insert]. Waltham, MA, USA: Alkermes, Inc.; 2018.
22. Correll CU. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence. *J Clin Psychiatry*. 2014; 75(11): e29.